{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:48:55Z","timestamp":1785552535427,"version":"3.56.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102461","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:36Z","timestamp":1762211076000},"page":"102461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gleason Score 3 + 4 (Grade Group 2) Prostate Cancer on Biopsy and Postoperative Pathological Upgrading: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Shulin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharron X.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0444-0068","authenticated-orcid":false,"given":"Chin-Lee","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102461_bib0001","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Availabe at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf Accessed 23 July 2024. 2024."},{"key":"10.1016\/j.clgc.2025.102461_bib0002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bju.14935","article-title":"Active surveillance in intermediate-risk prostate cancer","volume":"125","author":"Klotz","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2014.284","article-title":"Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate-Risk prostate cancer","volume":"1","author":"Raldow","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0006","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102461_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0008","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmed.2017.00157","article-title":"Prognostic value of the New Prostate Cancer International Society of Urological Pathology grade Groups","volume":"4","author":"Offermann","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clgc.2025.102461_bib0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0011","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0012","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5489\/cuaj.2806","article-title":"Active surveillance for the management of localized prostate cancer: guideline recommendations","volume":"9","author":"Morash","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2025.102461_bib0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-017-0726-3","article-title":"Active surveillance for intermediate risk prostate cancer","volume":"18","author":"Klotz","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clgc.2025.102461_bib0014","doi-asserted-by":"crossref","first-page":"e1117","DOI":"10.1016\/j.clgc.2017.07.020","article-title":"Favorable Gleason 3 + 4 prostate cancer shows comparable outcomes with Gleason 3 + 3 prostate cancer: implications for the expansion of selection criteria for active surveillance","volume":"15","author":"Lee","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102461_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12894-023-01314-6","article-title":"Active surveillance should be considered for select men with grade group 2 prostate cancer","volume":"23","author":"Pekala","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0016","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.3390\/cancers14174161","article-title":"Active surveillance in intermediate-risk prostate cancer: a review of the current data","volume":"14","author":"Blas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102461_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bju.13461","article-title":"Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI\/ultrasonography-fusion biopsy","volume":"118","author":"Borkowetz","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0018","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2008.03.049","article-title":"Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis","volume":"54","author":"Cohen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1464-410X.2006.06262.x","article-title":"Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation","volume":"98","author":"Chun","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0021","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0022","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/PAS.0b013e3182a02169","article-title":"Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma","volume":"37","author":"Dong","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0023","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/modpathol.2017.29","article-title":"Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer","volume":"30","author":"Kweldam","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0024","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/his.14064","article-title":"Clinical outcome comparison of grade group 1 and grade group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy","volume":"76","author":"Hollemans","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2025.102461_bib0025","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/PAS.0000000000000235","article-title":"Gleason score 3 + 4=7 prostate cancer with minimal quantity of Gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen","volume":"38","author":"Huang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0026","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/pin.13026","article-title":"Combination of total length of Gleason pattern 4 and number of Gleason score 3 + 4 = 7 cores detects similar outcome group to Gleason score 6 cancers among cases with >\/=5% of Gleason pattern 4","volume":"70","author":"Sato","year":"2020","journal-title":"Pathol Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0027","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2559.2009.03405.x","article-title":"The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice","volume":"55","author":"Zareba","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2025.102461_bib0028","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0029","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.juro.2014.07.098","article-title":"Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance","volume":"193","author":"Radtke","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0030","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clgc.2025.102461_bib0031","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2025.102461_bib0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2014.08.077","article-title":"Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients","volume":"67","author":"Baco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0033","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.juro.2014.04.094","article-title":"Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology","volume":"192","author":"Le","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0034","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2025.102461_bib0035","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2025.102461_bib0036","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.urology.2023.02.001","article-title":"Gleason grade group concordance between systematic template combining magnetic resonance imaging fusion targeted biopsy and radical prostatectomy specimens: a comparison of transperineal and transrectal approaches","volume":"175","author":"Wu","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102461_bib0037","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/bco2.195","article-title":"The highest percentage of Gleason Pattern 4 is a predictor in intermediate-risk prostate cancer","volume":"4","author":"Sato","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.clgc.2025.102461_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.02.017","article-title":"Pathologic upgrading in favorable intermediate risk active surveillance patients: clinical heterogeneity and implications for active surveillance decision","volume":"39","author":"Sayyid","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0039","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s11255-021-03007-1","article-title":"Gleason grade accuracy of transperineal and transrectal prostate biopsies in MRI-naive patients","volume":"53","author":"Qu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2025.102461_bib0040","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00345-020-03421-7","article-title":"Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3\u2009+\u20094","volume":"39","author":"Kim","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0041","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/pin.13026","article-title":"Combination of total length of Gleason pattern 4 and number of Gleason score 3 + 4 = 7 cores detects similar outcome group to Gleason score 6 cancers among cases with \u22655% of Gleason pattern 4","volume":"70","author":"Sato","year":"2020","journal-title":"Pathol Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0042","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/jcm9010225","article-title":"Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clgc.2025.102461_bib0043","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4111\/icu.2020.61.4.405","article-title":"Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: who is a candidate for active surveillance?","volume":"61","author":"Pham","year":"2020","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000503888","article-title":"Patients with biopsy Gleason score 3 + 4 are not appropriate candidates for active surveillance","volume":"104","author":"Park","year":"2020","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.05.027","article-title":"Pathological findings at radical prostatectomy of biopsy naive men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling","volume":"38","author":"Luzzago","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0046","doi-asserted-by":"crossref","first-page":"360","DOI":"10.23736\/S0393-2249.19.03367-8","article-title":"Risk of Gleason score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy","volume":"72","author":"De Luca","year":"2020","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.clgc.2025.102461_bib0047","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5858\/arpa.2017-0410-OA","article-title":"Prostate cancers detected by magnetic resonance imaging-targeted biopsies have a higher percentage of Gleason pattern 4 component and are less likely to Be upgraded in radical prostatectomies","volume":"143","author":"Zhao","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2025.102461_bib0048","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euf.2017.05.011","article-title":"Risk of upgrading and upstaging among 10000 patients with Gleason 3+4 favorable intermediate-risk prostate cancer","volume":"5","author":"Yang","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2025.102461_bib0049","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fsurg.2019.00055","article-title":"MRI-fusion targeted vs. systematic prostate biopsy-how does the biopsy technique affect Gleason grade concordance and upgrading after radical prostatectomy?","volume":"6","author":"Ruhrup","year":"2019","journal-title":"Front Surg"},{"key":"10.1016\/j.clgc.2025.102461_bib0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.juro.2018.09.042","article-title":"Defining intermediate risk prostate cancer suitable for active surveillance","volume":"201","author":"Loeb","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0051","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/pros.23905","article-title":"The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer","volume":"79","author":"Jang","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102461_bib0052","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2018.08.043","article-title":"PI-RADS version 2 category on 3 tesla multiparametric prostate magnetic resonance imaging predicts oncologic outcomes in Gleason 3 + 4 prostate cancer on biopsy","volume":"201","author":"Faiena","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0053","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00345-019-02634-9","article-title":"A multicentric study on accurate grading of prostate cancer with systematic and MRI\/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy","volume":"37","author":"Diamand","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0054","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.juro.2018.07.062","article-title":"Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer","volume":"201","author":"Dean","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0055","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.7150\/jca.26791","article-title":"Risk of upgrading from prostate biopsy to radical prostatectomy pathology: is magnetic resonance imaging-guided biopsy more accurate?","volume":"9","author":"Xu","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.clgc.2025.102461_bib0056","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/PAS.0000000000001137","article-title":"Concordance of ``case level'' global, highest, and largest volume cancer grade group on needle biopsy versus grade group on radical prostatectomy","volume":"42","author":"Trpkov","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0057","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamaoncol.2017.1879","article-title":"Adverse pathologic findings for men electing immediate radical prostatectomy: defining a favorable intermediate-risk group","volume":"4","author":"Patel","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0058","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4510149","article-title":"The impact of pathologic upgrading of Gleason score 7 prostate cancer on the risk of the biochemical recurrence after radical prostatectomy","volume":"2018","author":"Park","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0059","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.juro.2017.11.116","article-title":"Comparison of pathological and oncologic outcomes of favorable risk Gleason score 3 + 4 and low risk Gleason score 6 prostate cancer: considerations for active surveillance","volume":"199","author":"Gearman","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0060","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.juro.2017.10.014","article-title":"Most Gleason 8 biopsies are downgraded at prostatectomy-does 4 + 4 = 7?","volume":"199","author":"Gansler","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0061","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3 + 4 ``favorable intermediate-risk'' prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0062","doi-asserted-by":"crossref","first-page":"E1117","DOI":"10.1016\/j.clgc.2017.07.020","article-title":"Favorable Gleason 3+4 prostate cancer shows comparable outcomes with Gleason 3+3 prostate cancer: implications for the expansion of selection criteria for active surveillance","volume":"15","author":"Lee","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.clgc.2025.102461_bib0063","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bju.13460","article-title":"Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort","volume":"117","author":"Wong","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0064","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.04.058","article-title":"Extreme Gleason upgrading from biopsy to radical prostatectomy: a population-based analysis","volume":"96","author":"Winters","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102461_bib0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","article-title":"Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens","volume":"69","author":"Sauter","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0066","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.21873\/anticanres.11045","article-title":"Multiparametric-magnetic resonance\/ultrasound fusion targeted prostate biopsy improves agreement between biopsy and radical prostatectomy Gleason score","volume":"36","author":"Porpiglia","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2025.102461_bib0067","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prnil.2016.07.004","article-title":"Gleason group concordance between biopsy and radical prostatectomy specimens: a cohort study from Prostate Cancer Outcome Registry - Victoria","volume":"4","author":"Evans","year":"2016","journal-title":"Prostate Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0068","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/pcan.2015.21","volume":"18","author":"Schiavina","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"71","key":"10.1016\/j.clgc.2025.102461_bib0069","first-page":"e71","article-title":"Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients","volume":"33","author":"Ploussard","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00428-015-1809-5","article-title":"Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy","volume":"467","author":"Keefe","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2025.102461_bib0071","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00432-015-1991-5","article-title":"The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy","volume":"141","author":"Arsov","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0072","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/PAS.0000000000000235","article-title":"Gleason score 3+4=7 prostate cancer with minimal quantity of Gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen","volume":"38","author":"Huang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102461_bib0073","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3892\/mco.2014.370","article-title":"Upgrading and upstaging in prostate cancer: from prostate biopsy to radical prostatectomy","volume":"2","author":"D'Elia","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0074","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/21681805.2013.821628","article-title":"Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy","volume":"48","author":"Berg","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0075","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0076","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1464-410X.2011.10681.x","article-title":"The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume","volume":"110","author":"Corcoran","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0077","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.urolonc.2009.07.003","article-title":"Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series","volume":"29","author":"Tilki","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102461_bib0078","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urology.2010.05.030","article-title":"Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review","volume":"77","author":"Kuroiwa","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102461_bib0079","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1111\/j.1464-410X.2011.10119.x","article-title":"Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence","volume":"108","author":"Corcoran","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0080","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.juro.2011.05.075","article-title":"Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy","volume":"186","author":"Amin","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0081","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1464-410X.2009.08810.x","article-title":"Prostate cancer grading: the effect of stratification of needle biopsy Gleason score 4 + 3 as high or intermediate grade","volume":"105","author":"Fanning","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102461_bib0082","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2005.07.037","article-title":"Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate","volume":"67","author":"Gonzalgo","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102461_bib0083","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)64053-0","article-title":"Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy","volume":"169","author":"San Francisco","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0084","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2014.11.037","article-title":"Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis","volume":"68","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0086","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102461_bib0087","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JU.0000000000000359","article-title":"Multiparametric magnetic resonance imaging-ultrasound fusion biopsy improves but does not replace standard template biopsy for the detection of prostate cancer","volume":"202","author":"Hanna","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102461_bib0088","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.humpath.2021.08.008","article-title":"Transperineal multiparametric magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy combined with standard template improves perineural invasion detection","volume":"117","author":"Wu","year":"2021","journal-title":"Hum Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:57:28Z","timestamp":1768921048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001612"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102461","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gleason Score 3 + 4 (Grade Group 2) Prostate Cancer on Biopsy and Postoperative Pathological Upgrading: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102461"}}